



<div>  <div> Division of HIV, Infectious Diseases & Global Medicine Department of Medicine </div> </div> <div> HIV, ID and GLOBAL MEDICINE & AFFILIATES OPEN CLINICAL STUDIES </div> <div>  <div> ZUCKERBERG SAN FRANCISCO GENERAL Hospital and Trauma Center </div> </div>			
STUDY	BASIC CRITERIA	DESIGN	CONTACT
ACUTE / EARLY INFECTION STUDIES			
UCSF Treat Acute Study	Adults with new "recent" HIV diagnosis (last known HIV neg test within last 3-6 months); prior PrEP or PEP ok; already initiated on ART for HIV treatment ok as long as within 1 week of starting ART.	Phase IV open-label trial	sulggi.lee@ucsf.edu (415)735-5127; TREATACUTE@LISTSRV.UCSF.EDU (415) 443-5035
ANTIRETROVIRAL INTENSIFICATION, INFLAMMATION REDUCTION, AND HIV ERRADICATION			
DARE (Delaney AIDS Research Enterprise to cure HIV)	HIV+ able to undergo leukapheresis large blood draws and/or tissue biopsies. Acute or chronically treated, ART-suppressed >12 months or elite/viremic controllers (VL<2000 while not taking ART). Other criteria apply. Compensation provided.	A group of studies learning how & where HIV persists in the body. Multiple visits to measure HIV viral reservoirs via blood draws, leukapheresis, and tissue biopsies.	Call 415-476-4082, x139, or x104; email Rebecca.Hoh@ucsf.edu or Viva.Tai@ucsf.edu .
EMRLHD (Effect of Methamphetamine on Residual Latent HIV Disease) Study	HIV+ adults who use methamphetamine (smoke, IV, etc.) in a "binge" pattern (e.g., some months frequently each week and other months once or twice), ART suppressed at least 2 years, and current CD4>350, HIV VL<40, and not on protease inhibitor regimen. No contraindications for getting inguinal lymph node fine needle aspirate. Hair on head at least 2 inches long.	Cohort study. Longitudinal fine needle aspirate collections of inguinal lymph nodes, spaced approximately 6 months apart for a total of 3 lymph node collections.	sulggi.lee@ucsf.edu (415)735-5127; rebecca.hoh@ucsf.edu (415) 476-4082 ext. 139; heather.hartig@ucsf.edu (415) 476-4082 ext. 155; marian.kerbleski@ucsf.edu (415) 476-4082
EMRLHD (Effect of Methamphetamine on Residual Latent HIV Disease) Study	HIV+ adults with ART suppression at 2 years (no ART regimen change in prior 1 year), NO PRIOR history of meth dependence (ok if prior Adderall or Dexedrine for treatment of ADHD as long as over 1 year ago), no cardiac history, no hx of psychosis.	Phase I trial. Participants will be administered a total of 25 mg of oral methamphetamine in the Clinical Research Services Center.	sulggi.lee@ucsf.edu (415)735-5127; rebecca.hoh@ucsf.edu (415) 476-4082 ext. 139; heather.hartig@ucsf.edu (415) 476-4082 ext. 155
IDEO (Inflammation, Diabetes, Multi-Ethnic Obesity Cohort)	Enrolling HIV(+) & HIV(-), age 25-65 who do not currently have diabetes or active hepatitis. Other criteria apply. Compensation provided.	A study seeking to learn about body composition and metabolic complications in HIV across different ethnic groups. 4-6 visits for measurements of muscle, fat, and bone, and metabolic testing for insulin resistance.	Call 415-476-4082, ext. 340; Enrique.Martinez-Ortiz@ucsf.edu .
PENNVAX	HIV+ age 18-65, ART-suppressed >24 months, CD4>350 and CD4 nadir >200. Excellent venous access in both arms. Other criteria apply. Compensation provided	Evaluating safety, immunogenicity and anti-reservoir activity of a therapeutic HIV DNA vaccine vs placebo. Involves 1-2 screening visits, 2 leukaphereses, 4 vaccinations with electroporesis over 4 months, and follow-up blood draws over 12 months. No treatment interruptions are involved.	Call 415-476-4082 x139; Rebecca.Hoh@ucsf.edu .
ANTIRETROVIRAL TREATMENT STUDIES			
COMPLICATIONS AND CO-INFECTION STUDIES			

I AM OLD (Inflammation, Aging, Microbes and Obstructive Lung Disease)	HIV+, willing and able to undergo pulmonary function testing (PFTs), answer questions, and provide blood	Prospective, observational cohort study of HIV-associated chronic obstructive pulmonary disease (COPD)	Amanda Jan: 415-206-2485
HEPATITIS STUDIES			
SCOPE (Shingrix observation)	Any HIV infected individuals on ART	To enroll in SCOPE if planning to receive Shingrix vaccine for routine clinical care (not for research study) We will collect blood prior to and 48 hours post vaccine	415-206-5518 (Henrich)
IMMUNOLOGIC STUDIES			
OBSERVATIONAL AND OTHER STUDIES			
FNA (Fine Needle Aspiration)	HIV+, able to undergo FNA. Enrolling either 1) newly infected or 2) ART-suppressed > 6 months, or 3) elite/viremic controllers (VL<2000 not on ART). Other criteria apply. Compensation provided.	Involves 1-2 visits including 2-hour visit for FNA of inguinal lymph nodes using guided ultrasound and performed under local anesthetic. Lymph node aspirates will support multiple projects focused on viral reservoirs mechanisms of persistence and inflammation.	Call 415-476-4082, ext. 144; Marian.Kerbleski@ucsf.edu.
GALT (Gut Associated Lymphoid Tissue) Study	HIV+, willing/able to do flex sigs or colonoscopies. Enrolling acute or chronically treated & ART-suppressed > 12 months or) elite/viremic controllers (VL<2000 not on ART). Other criteria apply. Compensation provided.	Flexible sigmoidoscopy or colonoscopy performed by Ma Somsouk at ZSFGH GI Center. Research colonoscopy provides full cancer screen (same as a clinical colonoscopy). Tissue biopsies will support multiple projects focused on viral reservoirs mechanisms of persistence and inflammation.	Call 415-476-4082 x140; Montha.Pao@ucsf.edu.
HIPSTER (HIV Imaging: PET/MRI Scans To Evaluate Reservoirs)	Acute, Early or late infected individuals, Viremic individuals also required	PET-MR Imaging of HIV infection and immune activation	Tim Henrich 415-206-5518 or 415-476-4082, ext. 340; Enrique.Martinez-Ortiz@ucsf.edu.
Leukapheresis	HIV+ with excellent venous access in both arms and able to sit still for up to 3 hours. Enrolling 1) ART-suppressed > 12 months or 2) elite/viremic controllers (VL<2000 not on ART). Other criteria apply. Compensation provided.	Involves 2 visits including a screening visit and a 3-4 hour leukapheresis (white blood cell) collection. Lymph node aspirates will support multiple projects focused on viral reservoirs mechanisms of persistence and inflammation.	Call 415-476-4082 x139 or x 104; Rebecca.Hoh@ucsf.edu; Viva.Tai@ucsf.edu
SCOPE Study	Observational study recruiting 1) elite or viral controllers with VL<2000copies/mL & not taking ART, 2) ART-suppressed >12 months, or 3) individuals not taking ART with high viral loads.	Interviews & blood draws 2-3 times per year. Compensation provided.	Call 415-476-4082 x140 or x 155; email Montha.Pao@ucsf.edu or Heather.Hartig@ucsf.edu.
SCOPE (Shingrix observation)	Any HIV infected individuals on ART	To enroll in SCOPE if planning to receive Shingrix vaccine for routine clinical care (not for research study) We will collect blood prior to and 48 hours post vaccine	415-206-5518 (Henrich)